Orexo gains FDA's blessing for sublingual tablet; Purdue nanoparticles designed to react to tumor cell acidity;

> Orexo gained FDA approval for Zubsolv, a once-daily sublingual tablet designed to treat opioid dependence and dissolve quickly. Item

> Eisai says it has come up with a new "dry syrup" formulation using the artificial sweetener sucralose to help boost the likelihood that Alzheimer's patients will take their pills. Story

> Milestone Scientific and Tri-anim Health Services will partner to develop and market injection drug-delivery technology for epidural use during childbirth and other pain management treatments. Item

> Purdue University scientists believe they can deliver cancer drugs more effectively by relying on nanoparticles that both concentrate and expand when in contact with tumor cells' higher acidity. Release

> Catalent has created a new business unit--Advanced Delivery Technologies--that will focus on working with existing and new drug delivery technologies in the development process. Story

> Alliqua raised $3 million through a stock offering in the second quarter of 2013 to help expand its wound dressing portfolio and propel development of its transdermal drug delivery platform. Item

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.